387 related articles for article (PubMed ID: 29214759)
1. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
2. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
Nystrand CF; Ghanima W; Waage A; Jonassen CM
Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
[TBL] [Abstract][Full Text] [Related]
4. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
5. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of JAK2 V617F Allele Burden by Using the QuantStudio™ 3D Digital PCR System.
Kinz E; Muendlein A
Methods Mol Biol; 2018; 1768():257-273. PubMed ID: 29717448
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
8. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for
La Rocca F; Grieco V; Ruggieri V; Zifarone E; Villani O; Zoppoli P; Russi S; Laurino S; Falco G; Calice G; Marinaccio A; Natalicchio MI; Albano F; Musto P
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32150880
[No Abstract] [Full Text] [Related]
9. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
10. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
[TBL] [Abstract][Full Text] [Related]
11. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
15. Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms.
Yow KS; Liu X; Chai CN; Tung ML; Yan B; Christopher D; Ong KH; Ooi MG
Asian Pac J Cancer Prev; 2020 Sep; 21(9):2805-2810. PubMed ID: 32986384
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
17. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
18. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
19. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
[TBL] [Abstract][Full Text] [Related]
20. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
